{
    "ticker": "STRO",
    "name": "Sutro Biopharma, Inc.",
    "description": "Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of next-generation protein therapeutics. Founded in 2003 and headquartered in South San Francisco, California, Sutro leverages its innovative cell-free protein synthesis platform to create a diverse pipeline of antibody-drug conjugates (ADCs) and other biologic therapies. The company's proprietary technology allows for the rapid and efficient generation of complex proteins and peptides, which are essential for advancing therapeutic development in oncology and other diseases. Sutro's lead product candidate, STRO-001, is designed for the treatment of various hematological malignancies and is currently undergoing clinical trials. The company is committed to addressing unmet medical needs by transforming the development and manufacturing of biologics through its integrated approach. With a strong focus on collaboration, Sutro has established partnerships with leading pharmaceutical companies to enhance its research and development capabilities. The company aims to improve patient outcomes through its innovative therapies that target cancer and other serious illnesses.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2003",
    "website": "https://www.sutrobio.com",
    "ceo": "Dr. Bill Newell",
    "social_media": {
        "twitter": "https://twitter.com/sutrobio",
        "linkedin": "https://www.linkedin.com/company/sutro-biopharma/"
    },
    "investor_relations": "https://ir.sutrobio.com",
    "key_executives": [
        {
            "name": "Dr. Bill Newell",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael L. Heller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "STRO-001",
                "STRO-002"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sutro Biopharma, Inc. | Innovative Protein Therapeutics",
        "meta_description": "Sutro Biopharma, Inc. specializes in developing next-generation protein therapeutics using its proprietary technology platform for antibody-drug conjugates and other biologics.",
        "keywords": [
            "Sutro Biopharma",
            "Biotechnology",
            "Protein Therapeutics",
            "Antibody-Drug Conjugates",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Sutro Biopharma known for?",
            "answer": "Sutro Biopharma is known for developing next-generation protein therapeutics, including antibody-drug conjugates for cancer treatment."
        },
        {
            "question": "Who is the CEO of Sutro Biopharma?",
            "answer": "Dr. Bill Newell is the CEO of Sutro Biopharma, Inc."
        },
        {
            "question": "Where is Sutro Biopharma headquartered?",
            "answer": "Sutro Biopharma is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Sutro Biopharma's main products?",
            "answer": "Sutro Biopharma's main products include STRO-001 and STRO-002, which are in development for cancer treatment."
        },
        {
            "question": "When was Sutro Biopharma founded?",
            "answer": "Sutro Biopharma was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "INCY",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "NVS",
        "ABBV"
    ]
}